analytical methods is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-07. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Novel applications === Due to the versatility of SPR instrumentation, this technique pairs well with other approaches, leading to novel applications in various fields, such as biomedical and environmental studies. When coupled with nanotechnology, SPR biosensors can use nanoparticles as carriers for therapeutic implants. For instance, in the treatment of Alzheimer's disease, nanoparticles can be used to deliver therapeutic molecules in targeted ways. In general, SPR biosensing is demonstrating advantages over other approaches in the biomedical field due to this technique being label-free, lower in costs, applicable in point-of-care settings, and capable of producing faster results for smaller research cohorts. In the study of environmental pollutants, SPR instrumentation can be used as a replacement for former chromatography-based techniques. Current pollution research relies on chromatography to monitor increases in pollution in an ecosystem over time. When SPR instrumentation with a Kretschmann prism configuration was used in the detection of chlorophene, an emerging pollutant, it was demonstrated that SPR has similar precision and accuracy levels as chromatography techniques. Furthermore, SPR sensing surpasses chromatography techniques through its high-speed, straightforward analysis.
Rice (1932–2024), physical chemist Ellen Swallow Richards (1842–1911), industrial and environmental chemist Theodore William Richards (1868–1928), 1914 Nobel Prize in Chemistry Wim Richter (1946–2019), South Africa Jeremias Benjamin Richter (1762–1807), German chemist, first used the term stoichiometry Nikolaus Riehl (1901–1990), German chemist Andrés Manuel del Río (1764–1849), Spanish-Mexican geochemist, discovered vanadium Robert Robinson (1886–1975), British chemist, 1947 Nobel Prize in Chemistry Pierre Jean Robiquet (1780–1840), French chemist, discovered caffeine, alizarin, cantharidin Hillar Rootare (1928–2008), Estonian-American physical chemist Irwin Rose (1926–2015), 2004 Nobel Prize in Chemistry Guillaume-François Rouelle (1703–1770), French chemist Hilaire-Marin Rouelle (1718–1779), French chemist Frank Sherwood Rowland (1927–2012), 1995 Nobel Prize in Chemistry Daniel Rutherford (1749–1819), Scottish chemist Ernest Rutherford (1871–1937), New Zealand born chemist and nuclear physicist. Discovered the proton. Nobel Prize in Chemistry 1908 Leopold Ruzicka (Lavoslav Ružička) (1887–1976), 1939 Nobel Prize in Chemistry
Hunkapiller's idea would require competing against his own customers, to all of whom Applied Biosystems sold its sequencing machines and their chemical reagents. However, he calculated that it would also mean doubling the market for that equipment. Hunkapiller brought in Dr. J. Craig Venter to direct the project. Tony White, president of the Perkin-Elmer Corporation backed Hunkapiller on the venture. They organized the new company to accomplish the task. In May 1998, Celera Genomics was formed, to rapidly accelerate the human DNA sequencing process. Dr. Venter boldly declared to the media that he would complete the genome decoding by 2001. That bold announcement prompted the academic consortium to accelerate their own deadline by a couple years, to 2003. Also in 1998, PE Biosystems partnered with Hitachi, Ltd. to develop electrophoresis-based genetic analysis systems, which resulted in their chief new genomics instrument, the ABI PRISM 3700 DNA Analyzer, which advanced the Human Genome sequencing project by nearly five years ahead of schedule. The partnerships sold hundreds of the 3700 analyzers to Celera, and also to others worldwide. The new machine cost US$300,000 each, but was a major leap beyond its predecessor, the 377, and was fully automated, allowing genetic decoding to run around the clock with little supervision. According to Venter, the machine was so revolutionary that it could decode in a single day the same amount of genetic material that most DNA labs could produce in a year.
An independent panel upholds the Parliamentary Commissioner for Standards' decision that Scott Benton, MP for Blackpool South, should face a 35-day suspension from Parliament. The suspension will now be voted on by MPs and could trigger another by-election. Heather Woodbridge, aged 29, is appointed as leader of Orkney Islands Council, becoming Scotland's youngest council leader and the first woman to lead Orkney Islands Council. 21 February – An Opposition day House of Commons debate calling for a ceasefire in Gaza descends into chaos after Speaker Sir Lindsay Hoyle breaks with Parliamentary convention to allow a vote on a Labour amendment calling for an "immediate humanitarian ceasefire" over the scheduled SNP motion calling for an "immediate ceasefire". The decision leads to protests from both Conservative and SNP MPs, who walk out of the House, leaving Labour's motion to be nodded through when the other two parties do not take part in the vote. Amid calls for his resignation, Hoyle says that he allowed the House to vote on the Labour motion so MPs could express their view on "the widest range of propositions", and to protect MPs' safety. King Charles III is seen back at work and meeting Prime Minister Rishi Sunak, the first time he has been seen back at work since his cancer diagnosis. Senior civil servant Sarah Munby writes to the Business Secretary to reject allegations by former Post Office chairman Henry Staunton that he was told to delay compensation payments to victims of the Horizon scandal.
Sources: en.wikipedia.org
On 1 December 1978, the Health and Safety Executive announced their intention to prosecute the university for breach of safety legislation. The case was heard in October 1979 at Birmingham Magistrates' Court. Although the source of infection was traced, the mode and cause of transmission was not. Evidence presented by several internationally recognised experts, including Kevin McCarthy, Allan Watt Downie and Keith R. Dumbell, showed that airborne transmission from the laboratory to the telephone room where Parker was supposedly infected was highly improbable. The experts calculated that it would require 53,700 litres (11,812 imp gal) of virus fluid to have been aspirated (meaning, in this context, removed by suction of fluid and cells through a needle) and it would take 20,000 years for one particle to travel to the telephone room at the rate the fluid was aspirated. It was additionally found that although the Shooter Inquiry noted the poor state of the duct sealing in the laboratory, this was caused after the outbreak by engineers fumigating the laboratory and ducts. The university was found not guilty of causing Parker's death.
For fission of uranium-235, the predominant radioactive fission products include isotopes of iodine, caesium, strontium, xenon and barium. The threat becomes smaller with the passage of time. Locations where radiation fields once posed immediate mortal threats, such as much of the Chernobyl Nuclear Power Plant on day one of the accident and the ground zero sites of U.S. atomic bombings in Japan (6 hours after detonation) are now relatively safe because the radioactivity has decreased to a low level. Many of the fission products decay through very short-lived isotopes to form stable isotopes, but a considerable number of the radioisotopes have half-lives longer than a day. The radioactivity in the fission product mixture is initially mostly caused by short lived isotopes such as 131I and 140Ba; after about four months 141Ce, 95Zr/95Nb and 89Sr take the largest share, while after about two or three years the largest share is taken by 144Ce/144Pr, 106Ru/106Rh and 147Pm. Later 90Sr and 137Cs are the main radioisotopes, being succeeded by 99Tc. In the case of a release of radioactivity from a power reactor or used fuel, only some elements are released; as a result, the isotopic signature of the radioactivity is very different from an open air nuclear detonation, where all the fission products are dispersed.
===== Czech Republic ===== As of May 2023, the State Agricultural and Food Inspection of the Czech Republic is putting together broad regulations regarding a ban on CBD products. They will make it illegal to sell products containing cannabidiol and other cannabinoids derived from hemp, as a result of EU Novel Food Regulation. In case of Czech Republic, European Industrial Hemp Association has submitted an official request to the Czech Republic to recognize natural hemp extracts with cannabinoids as traditional food.
Sources: en.wikipedia.org
The Moskovskaya Okruzhnaya Zheleznaya Doroga (orbital railway line) has formed a ring around Moscow's current downtown since 1903. However, this line was a non-electrified, locomotive-only railway before reconstruction into the MCC during the 2010s. The Moscow Central Circle is a 54-kilometer (34 mi) orbital urban rail transit line that encircles historic Moscow. This line was built alongside the Little Ring of the Moscow Railway, incorporating some of its tracks. The MCC was opened for passenger use on 10 September 2016. The MCC line is operated by the Moscow government-owned company MKZD through the Moscow Metro, with the federal government-owned Russian Railways as the operations subcontractor.
After removing the skin, the unripe fruit can be sliced thin and deep fried in hot oil to produce chips. This thin preparation of plantain is known as tostones, patacones or plataninas in some of Central American and South American countries, platanutres in Puerto Rico, mariquitas or chicharritas in Cuba and chifles in Ecuador and Peru. However, in Cuba, the Dominican Republic, Guatemala, Puerto Rico, and Venezuela, tostones instead refers to thicker twice-fried patties (see below). In Cuba, plantain chips are called mariquitas. They are sliced thinly, and fried in oil until golden colored. They are popular appetizers served with a main dish. In Colombia they are known as platanitos and are eaten with suero atollabuey as a snack. Tostada refers to a green, unripe plantain which has been cut into sections, fried, flattened, fried again, and salted. These tostadas are often served as a side dish or a snack. They are also known as tostones or patacones in many Latin American countries. In Honduras, banana chips are called tajadas, which may be sliced vertically to create a variation known as plantain strips. In Africa, ipekere are plantain chips by the Yorubas It is made with varying stages of plantain, from very ripe, ripe to semi unripe and unripe. It is also fried as chips in various ways: plain, salted, seasoned or with various degrees of spiciness. There are different consistency in textures by preferences. Chips fried in coconut oil and sprinkled with salt, called upperi or kaya varuthathu, are a snack in South India in Kerala.
In a 2009 study of 683 children diagnosed in Beijing in 2008 with nephrolithiasis and 6,498 children without nephrolithiasis aged < 3 years, investigators found that in children exposed to melamine levels < 0.2 mg/kg per day, the risk for nephrolithiasis was 1.7 times higher than in those without melamine exposure, suggesting that the risk of melamine-induced nephrolithiasis in young children starts at a lower intake level than the levels recommended by the World Health Organization. In a study published in 2010, researchers from Beijing University studying ultrasound images of infants who fell ill in the 2008 contamination found that while most children in a rural Chinese area recovered, 12 per cent still showed kidney abnormalities six months later. "The potential for long-term complications after exposure to melamine remains a serious concern," the report said. "Our results suggest a need for further follow-up of affected children to evaluate the possible long-term impact on health, including renal function." Another 2010 follow-up study from Lanzhou University attributed the uric acid stone accumulation after ingestion of melamine to a rapid aggradation of metabolites such as cyanuric acid diamide (ammeline) and cyanuric acid and reported that urine alkalinization and stone liberalization were the most effective treatments. Until the 2007 pet food recalls, melamine had not routinely been monitored in food, except in the context of plastic safety or insecticide residue.
Although a further tiny energy gain could be extracted by synthesizing 62Ni, which has a marginally higher binding energy than 56Fe, conditions in stars are unsuitable for this process. Element production in supernovas greatly favor iron over nickel, and in any case, 56Fe still has a lower mass per nucleon than 62Ni due to its higher fraction of lighter protons. Hence, elements heavier than iron require a supernova for their formation, involving rapid neutron capture by starting 56Fe nuclei. In the far future of the universe, assuming that proton decay does not occur, cold fusion occurring via quantum tunnelling would cause the light nuclei in ordinary matter to fuse into 56Fe nuclei. Fission and alpha-particle emission would then make heavy nuclei decay into iron, converting all stellar-mass objects to cold spheres of pure iron.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.